Friday, September 26, 2025 |
7:00am |
Check-in and Breakfast in Exhibit Hall |
8:00am | Horizon CME App Overview and CE Housekeeping |
8:10am | Welcome, Introductions, & CE Housekeeping |
8:15am | (01) The Daniel D. Von Hoff Keynote Lecture: Protacs – include protein degrader products – molecular glues – multiple sessions – Prostate – hormonal and targeted agents also Breast as well » TBA |
9:15am | Break | Refreshments in Exhibit Hall |
| Block One: Small Molecules and Targeted Therapy |
9:40am | (02) Emerging Role of KAT6 Inhibitors in Cancer » TBA |
10:00am | (03) New Drugs in Lymphoma or subsets of Sarcomas Products from the clinical side / substitute products for MTAP + Bispecifics » TBA |
10:20am | (04) New USP1 and Selected PARP Inhibitors » Timothy Yap, MD – Professor, Department of Investigational Cancer Therapeutics (Phase I Program) Vice President, Head of Clinical Development, Associate Director, Translational Research, Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center |
10:40am | (05) Q+A Panel and Discussion: Block One » Faculty from Sessions 02 – 04 |
11:00am |
Gather for Lunch |
11:10am | Lunch |
11:55am | Dessert – Refreshments in Exhibit Hall |
| Block Two: Emerging Immunotherapeutic Platforms |
12:10pm | (06) New Oncolytic Vaccines on the Horizon » TBA |
12:30pm | (07) Emerging Role of Peptides and NeoAntigen Vaccines » TBA |
12:50pm | (08) Cell Targets in Solid Tumors » TBA |
1:20pm | (09) Q+A Panel and Discussion: Block Two » Faculty for Sessions 06 – 08 |
1:40pm | Message from the Cancer Charities |
1:55pm | Break – Trivia for Charity in the Exhibit Hall |
| Block Three: Recent Precision Medicine Advances in Hematology/Oncology |
2:15pm | (10) Lung Cancers » TBA |
2:35pm | (11) Breast Cancers » TBA |
2:55pm | (12) GI Cancers – specifically colorectal or gastric? » TBA |
3:15pm | (13) Acute Leukemia or MDS MPNS » Eytan Stein, MD – Hematologist-Oncologist Director, Drug Development in Leukemia Memorial Sloan Kettering Cancer Center |
3:35pm | (14) Q+A Panel and Discussion: Block Three » Faculty from Sessions 10 – 13 |
| Block Four: Clinical Advances in RAS Targeting |
3:55pm | (15) RAS ON Inhibitors » TBA |
4:15pm | (16) RAS Protacs and Molecular Glues » TBA |
4:35pm | (17) RAS Enzymatic Inhibitors » TBA |
4:55pm | (18) Q+A Panel and Discussion: Block Four » Faculty from Sessions 15 – 17 |
5:15pm | Networking Reception – Exhibit Hall |
Saturday, September 27, 2025 |
7:00am | Check-in |
7:10am | Breakfast Symposium sponsored by TBA » TBA |
7:55am | Horizon CME App Overview and CE Housekeeping |
8:00am | Welcome and Introductions |
| Block Five: Biomarker Methodology in Cancer |
8:10am | (19) ctDNA Applications in Management of Advanced Disease Patients on Investigational Agents – heme perspective – Myeloma – MRD end point » TBA |
8:30am | (20) AI as a Predictive Model in Drug Targets » TBA |
8:50am | (21) Companion Diagnostic Development » TBA |
9:10am | (22) Digitial Molecular Pathology » TBA |
9:30am | (23) Q+A Panel and Discussion: Block Five » Faculty from Sessions 19 – 22 |
9:50am | Break – Refreshments in the Exhibit Hall |
10:10am | Poster Session |
| Block Six: Clinical Trial Methodology |
10:55am | (24) Strategies for Patient Recruitment » Kelly Bolton, MD, PhD – Assistant Professor Washington University |
11:15am | (25) Novel Endpoints for Therapeutic Response in Early Phase Trials » TBA |
11:35am | (26) The Evolution of Agnostic Drug Approval: Where Are We Now? » TBA |
11:55am | (27) Role of Patient Advocacy in Early Phase Trials » TBA |
12:15pm | (28) Q+A Panel and Discussion: Block Six » Faculty from Sessions 24 – 27 |
12:35pm | Gather for Lunch |
12:45pm |
Buffet Lunch & Non-CME/CE Presentation Sponsored by TBA » TBA |
1:30pm | Dessert Break in Exhibit Hall |
| Block Seven: Antibody Drug Conjugates and Other Drugs Targeting the Cell Surface |
1:50pm | (29) Radiopharmaceuticals in Drug Development » TBA |
2:10pm | (30) Innovations in HER2 Targeted Therapy » TBA |
2:30pm | (31) Pre-Clinical Considerations in ADC Development » TBA |
2:50pm | (32) Clinical Advances in ADC Development and Novel Payloads » TBA |
3:10pm | Break – Refreshments in the Exhibit Hall |
3:30pm | (33) Novel Combination Approaches for ADC Therapeutics + Novel ADC Targets in Solid Tumors » TBA |
3:50pm | (34) Toxicity Management Considerations with Current ADC Landscape – combine with payloads » TBA |
4:10pm | (35) Q+A Panel and Discussion: Block Seven » Faculty from Sessions 31 – 36 |
4:30pm | Closing Comments |